Metabolic abnormalities in autosomal dominant polycystic kidney disease

Nephrology Dialysis Transplantation

Volumn 30, Issue 2, 2015, Pages 197-203

  Mao, Zhiguo ^a   Xie, Guoqiang ^a   Ong, Albert C M ^b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ADPKD; calculi; lipids; NODAT; uric acid

Indexed keywords

ANTIANEMIC AGENT; AZATHIOPRINE; CITRATE POTASSIUM; CITRIC ACID; ERYTHROPOIETIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATE; PRAVASTATIN; PREDNISONE; RAPAMYCIN; SIMVASTATIN; URATE;

ACIDURIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; GLUCOSE METABOLISM; GOUT; HUMAN; HYPERURICEMIA; HYPOCITRATURIA; HYPOPHOSPHATEMIA; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LIPID METABOLISM; METABOLIC DISORDER; NEPHROLITHIASIS; NEW ONSET DIABETES AFTER TRANSPLANTATION; NONHUMAN; POSTTRANSPLANT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; URINARY EXCRETION; COMPLICATION; INTRACRANIAL ANEURYSM; METABOLIC SYNDROME X; METABOLISM;

HUMANS; INTRACRANIAL ANEURYSM; METABOLIC SYNDROME X; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 84922512076     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu044     Document Type: Review

References (70)

1. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329: 332-342
2. Hughes J, Ward CJ, Peral B et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet 1995; 10: 151-160
3. Mochizuki T, Wu G, Hayashi T et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272: 1339-1342
4. Chang MY, Ong AC. New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol 2013; 76: 524-535
5. Ong AC, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 2005; 67: 1234-1247
6. Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis 2001; 38: 777-784
7. Ducloux D, Motte G, Vautrin P et al. Polycystic kidney disease as a risk factor for post-Transplant diabetes mellitus. Nephrol Dial Transplant 1999; 14: 1244-1246
8. De Mattos AM, Olyaei AJ, Prather JC et al. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int 2005; 67: 714-720
9. Hamer RA, Chow CL, Ong AC et al. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007; 83: 36-40
10. Caillard S, Eprinchard L, Perrin P et al. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation 2011; 91: 757-764
11. Gentil MA, Luna E, Rodriguez-Algarra G et al. Incidence of diabetes mellitus requiring insulin treatment after renal transplantation in patients with hepatitis C. Nephrol Dial Transplant 2002; 17: 887-891
12. Pietrzak-Nowacka M, Safranow K, Rozanski J et al. Autosomal dominant polycystic kidney disease is not a risk factor for post-Transplant diabetes mellitus. Matched-pair design multicenter study. Arch Med Res 2008; 39: 312-319
13. Bayer ND, Cochetti PT, Anil Kumar MS et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010; 90: 861-866
14. Ruderman I, Masterson R, Yates C et al. New onset diabetes after kidney transplantation in autosomal dominant polycystic kidney disease: a retrospective cohort study. Nephrology (Carlton) 2012; 17: 89-96
15. Hjelmesaeth J, Hartmann A. Insulin resistance in patients with adult polycystic kidney disease. Nephrol Dial Transplant 1999; 14: 2521-2522
16. Vareesangthip K, Tong P, Wilkinson R et al. Insulin resistance in adult polycystic kidney disease. Kidney Int 1997; 52: 503-508
17. Pietrzak-Nowacka M, Safranow K, Byra E et al. Glucose metabolism parameters during an oral glucose tolerance test in patients with autosomal dominant polycystic kidney disease. Scand J Clin Lab Invest 2010; 70: 561-567
18. Vareesangthip K, Thomas TH, Tong P et al. Erythrocyte membrane fluidity in adult polycystic kidney disease: difference between intact cells and ghost membranes. Eur J Clin Invest 1996; 26: 171-173
19. Vareesangthip K, Thomas TH, Wilkinson R. Abnormal effect of thiol groups on erythrocyte Na/Li countertransport kinetics in adult polycystic kidney disease. Nephrol Dial Transplant 1995; 10: 2219-2223
20. Ong AC, Ward CJ, Butler RJ et al. Coordinate expression of the autosomal dominant polycystic kidney disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue. Am J Pathol 1999; 154: 1721-1729
21. Fliser D, Pacini G, Engelleiter R et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347
22. Menon V, Rudym D, Chandra P et al. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 7-13
23. Jayapalan S, Saboorian MH, Edmunds JW et al. High dietary fat intake increases renal cyst disease progression in Han:SPRD-cy rats. J Nutr 2000; 130: 2356-2360
24. Allen E, Piontek KB, Garrett-Mayer E et al. Loss of polycystin-1 or polycystin-2 results in dysregulated apolipoprotein expression in murine tissues via alterations in nuclear hormone receptors. Hum Mol Genet 2006; 15: 11-21
25. Yoo KH, Kim YN, Lee MJ et al. Identification of apolipoproteinA1 reduction in the polycystic kidney by proteomics analysis of the Mxi1-deficient mouse. Proteomics 2009; 9: 3824-3832
26. Torres VE, Grantham JJ, Chapman AB et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 640-647
27. Schrier RW, Levi M. Lipids and renal cystic disease. Nephrol Dial Transplant 2010; 25: 3490-3492
28. Stocker R, Keaney JF, Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478
29. Peluso I, Morabito G, Urban L et al. Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. Endocr Metab Immune Disord Drug Targets 2012; 12: 351-360
30. Wang D, Strandgaard S, Borresen ML et al. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 2008; 51: 184-191
31. Maser RL, Vassmer D, Magenheimer BS et al. Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease. J Am Soc Nephrol 2002; 13: 991-999
32. Brookes ZL, Ruff L, Upadhyay VS et al. Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone. Am J Physiol Heart Circ Physiol 2013; 304: H33-H41
33. Van Dijk MA, Kamper AM, Van Veen S et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001; 16: 2152-2157
34. Zafar I, Tao Y, Falk S et al. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol 2007; 293: F854-F859
35. Fassett RG, Coombes JS, Packham D et al. Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scand J Urol Nephrol 2010; 44: 56-61
36. Cadnapaphornchai MA, George DM, Masoumi A et al. Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants. Contemp Clin Trials 2011; 32: 437-445
37. Natoli TA, Smith LA, Rogers KA et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med 2010; 16: 788-792
38. Torres VE, Erickson SB, Smith LH et al. The association of nephrolithiasis and autosomal dominant polycystic kidney disease. Am J Kidney Dis 1988; 11: 318-325
39. Grampsas SA, Chandhoke PS, Fan J et al. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 36: 53-57
40. Nishiura JL, Neves RF, Eloi SR et al. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 838-844
41. Ogbron MR, Sareen S, Prychitko J et al. Altered organic anion and osmolyte content and excretion in rat polycystic kidney disease: an NMR study. Am J Physiol 1997; 272(1 Pt 2):F63-F69
42. Tanner GA. Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 1998; 9: 1242-1248
43. Tanner GA, Tanner JA. Citrate therapy for polycystic kidney disease in rats. Kidney Int 2000; 58: 1859-1869
44. Torres VE, Wilson DM, Hattery RR et al. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1993; 22: 513-519
45. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301
46. Preuss H, Geoly K, Johnson M et al. Tubular function in adult polycystic kidney disease. Nephron 1979; 24: 198-204
47. Olteanu D, Liu X, LiuWet al. Increased Na+/H+ exchanger activity on the apical surface of a cilium-deficient cortical collecting duct principal cell model of polycystic kidney disease. Am J Physiol Cell Physiol 2012; 302: C1436-C1451
48. Avner ED, McDonough AA, Sweeney WE, Jr. Transport, cilia, and PKD: must we in (cyst) on interrelationships?. Focus on "Increased Na+/H+ exchanger activity on the apical surface of a cilium-deficient cortical collecting duct principal cell model of polycystic kidney disease". Am J Physiol Cell Physiol 2012; 302: C1434-5
49. Newcombe DS. Letter: gouty arthritis and polycystic kidney disease. Ann Intern Med 1973; 79: 605
50. Rivera JV, Martinez Maldonado M, Ramirezdearellano GA et al. Association of hyperuricemia and polycystic kidney disease. Bol Asoc Med P R 1965; 57: 251-262
51. Mejias E, Navas J, Lluberes R et al. Hyperuricemia, gout, and autosomal dominant polycystic kidney disease. Am J Med Sci 1989; 297: 145-148
52. Hosoya T, Ichida K, Tabe A et al. A study of uric acid metabolism and gouty arthritis in patients with polycystic kidney. Nihon Jinzo Gakkai Shi 1993; 35: 43-48
53. Meijer E, Rook M, Tent H et al. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5: 1091-1098
54. Torres VE, King BF, Chapman AB et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007; 2: 112-120
55. Kanbara A, Miura Y, Hyogo H et al. Effect of urine pH changed by dietary intervention on uric acid clearance mechanism of pH-dependent excretion of urinary uric acid. Nutr J 2012; 11: 39
56. Helal I, McFann K, Reed B et al. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 2013; 28: 380-385
57. Kaehny WD, Tangel DJ, Johnson AM et al. Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates. Am J Med 1990; 89: 49-52
58. Mavromatidis K, Magoula I, Tsapas G. Urate homeostasis in polycystic kidney disease: comparison with chronic glomerulonephritic kidney. Ren Fail 2002; 24: 447-459
59. Lee YH, Song GG. Pathway analysis of genome-wide association studies on uric acid concentrations. Hum Immunol 2012; 73: 805-810
60. Woodward OM, Kottgen A, Coresh J et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA 2009; 106: 10338-10342
61. Pavik I, Jaeger P, Kistler AD et al. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int 2011; 79: 234-240
62. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
63. Park SJ, Kim JH, Ha TS et al. Hypophosphatemia in patients with autosomal dominant polycystic kidney disease: the role of fibroblast growth factor 23 or loss of sodium/phosphate cotransporter?. Kidney Int 2011; 80: 554-555; discussion 555
64. Vogel M, Kranzlin B, Biber J et al. Altered expression of type II sodium/phosphate cotransporter in polycystic kidney disease. J Am Soc Nephrol 2000; 11: 1926-1932
65. Eckardt KU, Mollmann M, Neumann R et al. Erythropoietin in polycystic kidneys. J Clin Invest 1989; 84: 1160-1166
66. Chandra M, Miller ME, Garcia JF et al. Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron 1985; 39: 26-29
67. Poesen R, Bammens B, Claes K et al. Prevalence and determinants of anemia in the immediate postkidney transplant period. Transpl Int 2011; 24: 1208-1215
68. Hatamizadeh P, Ravel V, Lukowsky LR et al. Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant 2013; 28: 2889-2898
69. Shah A, Molnar MZ, Lukowsky LR et al. Hemoglobin level and survival in hemodialysis patients with polycystic kidney disease and the role of administered erythropoietin. Am J Hematol 2012; 87: 833-836
70. Bernhardt WM, Wiesener MS, Weidemann A et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol 2007; 170: 830-842